| 1 |
29196297 | Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS-Mutant Cancers. | 2018 Mar 1 |
3 |
| 2 |
29463989 | Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development. | 2018 |
1 |
| 3 |
27178121 | Two-Step Forward Genetic Screen in Mice Identifies Ral GTPase-Activating Proteins as Suppressors of Hepatocellular Carcinoma. | 2016 Aug |
1 |
| 4 |
22941213 | Differential inhibitory effects of two Raf-targeting drugs, sorafenib and PLX4720, on the growth of multidrug-resistant cells. | 2013 Jan |
1 |
| 5 |
22753710 | The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment. | 2012 Jul |
2 |
| 6 |
22960170 | An adaptive Src-PDGFRA-Raf axis in rhabdomyosarcoma. | 2012 Sep 28 |
1 |
| 7 |
21593445 | Constitutive ERK activity induces downregulation of tristetraprolin, a major protein controlling interleukin8/CXCL8 mRNA stability in melanoma cells. | 2011 Sep |
1 |
| 8 |
20201822 | Raf inhibitors as therapeutic agents against neurodegenerative diseases. | 2010 Mar |
1 |
| 9 |
15171791 | Use of mitogenic cascade blockers for treatment of C-Raf induced lung adenoma in vivo: CI-1040 strongly reduces growth and improves lung structure. | 2004 Jun 1 |
1 |